These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 11454684)

  • 21. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Feb; 9(2):716-21. PubMed ID: 12576440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
    Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases.
    Bando H; Weich HA; Horiguchi S; Funata N; Ogawa T; Toi M
    Oncol Rep; 2006 Mar; 15(3):653-9. PubMed ID: 16465426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
    Linderholm B; Tavelin B; Grankvist K; Henriksson R
    Br J Cancer; 1999 Oct; 81(4):727-32. PubMed ID: 10574263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
    de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
    Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
    Yamashita H; Nishio M; Ando Y; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
    Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis.
    Qin C; Wilson C; Blancher C; Taylor M; Safe S; Harris AL
    Clin Cancer Res; 2001 Apr; 7(4):818-23. PubMed ID: 11309328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D; Nicosia RF; Nicosia SV
    Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
    Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.